Different people require different prevention options
In the Western Cape this week, a twice-yearly injection called Lenacapavir began reaching clinics in communities where HIV has long found fertile ground in inequality. The province is offering young women and adolescent girls an alternative to the daily discipline of oral prevention — a quieter, less visible form of protection that health authorities hope will reach those the old approach never could. It is a medical advance, but also a social one: an acknowledgment that the shape of a tool matters as much as its efficacy, and that prevention must meet people inside the actual conditions of their lives.
- An estimated 111,000 people living with HIV in the Western Cape have fallen out of care entirely, exposing a fragile treatment chain that threatens years of hard-won progress.
- Daily oral PrEP has long been available but quietly rejected by many young women — not because it doesn't work, but because stigma, side effects, and the burden of daily adherence make it feel impossible to sustain.
- Lenacapavir's twice-yearly injection format strips away the daily friction, offering a form of protection that requires no pill bottle to hide and no explanation to give.
- The 22 clinics chosen for the rollout sit in neighborhoods — Khayelitsha, Nyanga, Gugulethu, Delft — where poverty, unemployment, and transactional relationships have kept transmission stubbornly high for decades.
- The injection's protection is real but conditional: miss a follow-up dose and the window closes, meaning the program's success hinges on community trust, sustained funding, and the unglamorous work of keeping people engaged.
The Western Cape health department this week began rolling out Lenacapavir — a twice-yearly HIV prevention injection — across 22 clinics in the province's highest-burden communities. It marks a meaningful shift in approach: rather than a daily pill, two injections a year, with no bottle to carry or explain. Health authorities believe this change in format could reach people that oral PrEP never did.
For years, daily pre-exposure prophylaxis has been both available and effective, yet many young women have quietly avoided it — deterred by fears of side effects, the stigma of visible medication, or simply the difficulty of daily adherence. Lenacapavir removes those frictions. Amelia Mfiki of the Provincial Council on AIDS and TB framed it as an expansion of choice: different people need different tools, and the real power lies in letting people decide what works for their lives.
The clinics selected — in places like Khayelitsha, Gugulethu, Nyanga, and Delft — sit in neighborhoods where HIV has circulated through sexual networks for decades. Professor Linda-Gail Bekker of the Desmond Tutu HIV Centre described the epidemiology plainly: these are communities where unemployment is high, economic vulnerability is the norm, and young women without income sometimes depend on male partners for survival, narrowing their ability to negotiate safer sex. Poverty amplifies risk in multiple directions. The Western Cape has the lowest HIV prevalence in South Africa, yet an estimated 540,000 people live with the virus there — and roughly 111,000 have not accessed any care in two years.
Bekker was clear about the injection's implicit condition: protection lasts only if people return for follow-up doses. Miss an appointment, and the window closes. That means success depends not on the drug alone, but on whether communities trust the program, whether education reaches those who need it, and whether funding holds. Health minister Mireille Wenger called it one of the most significant advances in HIV prevention in recent years. That may be so — but in communities where trust in institutions is fragile and every clinic visit is a logistical challenge, the injection is only the beginning. The harder work of keeping people engaged will determine whether this tool transforms outcomes or simply adds to a list of options available only to those already closest to care.
The Western Cape health department opened its doors to a new kind of HIV prevention this week—not a daily pill, but an injection given twice a year. On Monday, Lenacapavir began rolling out across 22 clinics in the province's highest-burden communities, marking the start of what officials hope will be a turning point in how young women and adolescent girls protect themselves from infection.
For years, oral pre-exposure prophylaxis, or PrEP, has been available and effective. But it requires discipline: a pill every single day. Many young women have avoided it, deterred by fears of side effects, the stigma of carrying medication, or simply the friction of daily adherence. Lenacapavir changes the equation. Two injections a year. No daily reminder. No pill bottle to hide or explain. Health authorities believe this shift in format could reach people the old approach never did.
The 22 clinics selected for this first phase—places like Khayelitsha Site B, Gugulethu, Nyanga, and Delft—sit in neighborhoods where HIV has been circulating through sexual networks for decades. Professor Linda-Gail Bekker, director of the Desmond Tutu HIV Centre at the University of Cape Town, described the epidemiology plainly: these are places where the virus has found stable ground. The reasons are structural, not moral. Unemployment is high. Economic vulnerability is the norm. Young women without jobs sometimes depend on male partners for survival, which narrows their ability to negotiate safer sex. Transactional relationships—sex in exchange for money or survival—are common. Poverty itself amplifies risk: high alcohol use, for instance, correlates with transmission. "HIV is not only a disease of poverty," Bekker said, but in these communities, the density of infection is undeniable, and that density is rooted in inequality.
The Western Cape still has the lowest HIV prevalence rate in South Africa, yet an estimated 540,000 people are living with the virus in the province. That number alone would be alarming; what makes it worse is the gap in care. Last December, the health department disclosed that about 111,000 people living with HIV had not accessed any care in the previous two years—a rupture in the treatment chain that threatens progress toward the global 95-95-95 targets, which aim for 95% of people with HIV to know their status, 95% of those diagnosed to be on treatment, and 95% of those on treatment to achieve viral suppression.
Lenacapavir is being positioned as one piece of a larger prevention strategy that already includes testing, treatment programs, condom distribution, and oral PrEP. But it is a significant piece. Amelia Mfiki, co-chairperson of the Provincial Council on AIDS and TB, framed it as an expansion of choice: different people need different tools, and for some, a six-monthly injection is simply easier to manage than daily medication. The real power, she suggested, lies in letting people decide what works for their lives.
Yet the rollout carries an implicit condition. Bekker was clear: the injection offers long-lasting protection, but only if people return for their follow-up doses. Miss an appointment, and the window of protection closes. That means the success of this program depends not just on the drug itself, but on whether clinics can keep people engaged, whether communities trust the program, whether education reaches the people who need it most. It depends on sustained funding, on partnerships between researchers and communities, on government support that doesn't waver.
Western Cape health minister Mireille Wenger called the rollout "one of the most significant advances in HIV prevention in recent years." That may be true. But advances in medicine are only as good as their reach. In communities where trust in institutions is fragile, where poverty makes every appointment a logistical challenge, where stigma still clings to HIV prevention, the injection is just the beginning. What comes next—the work of actually getting people to clinics, keeping them there, and sustaining the program—will determine whether this tool becomes transformative or merely another option available only to those already closest to care.
Citas Notables
HIV has been circulating in these communities for a long time. There comes a point where, unless you have highly effective prevention and treatment interventions, the virus continues to circulate within sexual networks.— Professor Linda-Gail Bekker, Desmond Tutu HIV Centre
For a long period, people can be adequately protected, but it remains important that they return for refills. We also need educational interventions to ensure people know what prevention tools are available to them.— Professor Linda-Gail Bekker
La Conversación del Hearth Otra perspectiva de la historia
Why does a twice-yearly injection matter more than a daily pill, if both work?
Because adherence is not just about biology—it's about life. A pill requires you to remember, to carry it, to take it in front of others sometimes. An injection twice a year is a clinic visit, a conversation, a moment of intentional care. For young women navigating poverty and economic dependence, that difference is real.
But doesn't the injection still require people to show up? That seems like its own barrier.
Absolutely. That's why this isn't just about the drug. It's about whether clinics can keep people engaged, whether they feel safe there, whether the system actually works for them. Missing one appointment means losing protection.
The article mentions 111,000 people with HIV who haven't accessed care in two years. How does Lenacapavir reach them?
It doesn't, not directly. Those people are already disconnected from the system. Lenacapavir is aimed at people at risk of infection—adolescent girls and young women who haven't been diagnosed yet. It's prevention, not treatment. But it does suggest the province is thinking about barriers: if daily pills don't work, maybe something different will.
What's the role of poverty here? The article keeps circling back to it.
Poverty isn't incidental to the HIV story in these communities—it's central. When you're unemployed and economically vulnerable, you may not be able to refuse unsafe sex. You may not be able to negotiate with a partner. You may be in a relationship that's transactional by necessity. Those conditions create the conditions for transmission. An injection doesn't change any of that.
So what does change it?
That's the harder question. The injection is a tool. But real change requires addressing the inequality underneath—jobs, education, economic security, the ability to say no. The health department knows this. That's why they're calling this part of a broader strategy, not a silver bullet.
What happens if people don't come back for their second injection?
Then they lose protection. The drug only works if you maintain it. That's why education and trust matter so much. If people don't believe in the program, or if clinics are too far away, or if life gets in the way, the whole thing falls apart.